The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases

Authors

  • Ghazwan Butrous 1. Professor of Cardiopulmonary Sciences; School of Pharmacy, University of Kent, Canterbury, Kent, CT2 7NJ, UK 2. Pulmonary Vascular Research Institute, Canterbury, Kent, United Kingdom

Abstract

Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

Downloads

Published

2017-06-30

Issue

Vol. 2014 No. 3 (2014)

Section

Review articles

License

This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.